BridgeMD
New treatment option for Eczema
Official title Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients
ClinicalTrials.gov ID: NCT06702293
What this study is testing
- What it's testing
- Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 and older
You may be able to join if
- Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist
- Aged 16 or older
- Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)
- Able to engage with a mobile application in the English language
You likely can't join if
- Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)
- Patients with unstable psychiatric condition, characterized by o Hospital inpatient admission for a psychiatric condition or initiation of a...
- Patients with unstable dermatological condition, characterized by
- Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics...
- Any of the following within 3 months
- inpatient admission for a dermatological condition
See the full eligibility criteria
- Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist
- Aged 16 or older
- Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)
- Able to engage with a mobile application in the English language
- Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)
- Patients with unstable psychiatric condition, characterized by o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months
- Patients with unstable dermatological condition, characterized by
- Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of...
- Any of the following within 3 months
- inpatient admission for a dermatological condition
- Initiation of phototherapy
- Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Singapore, Singapore, Singapore
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore, Singapore, Singapore. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.